Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
Corporate Updates
Previous
Next
In the News
- May 20, 2022
- CTV News
Burnaby company granted Health Canada licence to produce ‘magic mushroom medicine’
Kevin Charach
Imperial College study on psilocybin for depression highlights need for Real-World Evidence trials
- March 15, 2022
- Microdose
Is the UK Becoming a Global Center for Psychedelic Medicine?
Freddie Earlam
- February 9, 2022
- Truffle Report
Using Real-World Evidence to Accelerate Psychedelic Drug Development
Emily Jarvie
- November 30, 2021
- Psychedelic Health
Albert Labs receives conditional approval for CSE listing
Stephanie Price
- November 29, 2021
- Benzinga
Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
Javier Hasse
Previous
Next
Industry News
- October 22, 2022
- The Lancet
The Lancet Commission on Ending Stigma and Discrimination in Mental Health
Prof Graham Thornicroft PhD, Charlene Sunkel NSC, et al.
- October 12, 2022
- PSYCH
The MHRA’s Innovation Passport
- October 10, 2022
- Monash University
The Magic Mushroom Experience: Taking Psilocybin for Science
Devon Stoliker, Adeel Razi
- September 27, 2022
- The Economist
Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer
Alok Jha
Previous
Next